Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KMD-140
- Development stage
- Preclinical
- Lead developer
- KMD Bio
- Modality
- Nanoparticles → Drug Delivery Systems
01
Overview
KMD-140 is a preclinical-stage biologic candidate being developed by KMD Bio for the treatment of head and neck cancer. The drug is designed using KMD Bio's proprietary Protein Corona Shield Nanoparticle (PCSN) platform, also referred to as Antibody Conjugated NanoParticles (ACNP). This platform utilizes porous silica nanoparticles (MSNs) loaded with a cytotoxic payload and coated with targeting proteins via a stable glutathione-sensitive GST-GSH bio-linker, aiming to improve drug delivery efficiency and safety compared to traditional antibody-drug conjugates (ADCs). KMD-140 is currently undergoing preclinical and chemistry, manufacturing, and controls (CMC) development.
Beyond the preview
Go deeper on KMD-140.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KMD-140.